Search
SectionsIndex
  • Behavior
  • Circulatory System
  • Clinical Pathology and Procedures
  • Digestive System
  • Emergency Medicine and Critical Care
  • Endocrine System
  • Exotic and Laboratory Animals
  • Eye and Ear
  • Generalized Conditions
  • Immune System
  • Integumentary System
  • Management and Nutrition
  • Metabolic Disorders
  • Musculoskeletal System
  • Nervous System
  • Pharmacology
  • Poultry
  • Reproductive System
  • Respiratory System
  • Toxicology
  • Urinary System
  • Zoonoses
ABCDEFGHI
JKLMNOPQR
STUVWXYZ
In This Topic
Pharmacology
Antineoplastic Agents
Treatment of Canine Lymphoma
Back to Top
Resources
  • About The Merck Veterinary Manual
  • Reference Guides
  • Multimedia
Manuals available online
'/home/index.html' + bookPageLink
 
'/vet/index.html'
These and other Manuals available
in print, online, and as mobile applications.

See more at MerckManuals.com
Sections in Veterinary Professionals
  • Behavior
  • Circulatory System
  • Clinical Pathology and Procedures
  • Digestive System
  • Emergency Medicine and Critical Care
  • Endocrine System
  • Exotic and Laboratory Animals
  • Eye and Ear
  • Generalized Conditions
  • Immune System
  • Integumentary System
  • Management and Nutrition
  • Metabolic Disorders
  • Musculoskeletal System
  • Nervous System
  • Pharmacology
  • Poultry
  • Reproductive System
  • Respiratory System
  • Toxicology
  • Urinary System
  • Zoonoses
Chapters in Pharmacology
  • Pharmacology Introduction
  • Systemic Pharmacotherapeutics of the Cardiovascular System
  • Systemic Pharmacotherapeutics of the Digestive System
  • Systemic Pharmacotherapeutics of the Eye
  • Systemic Pharmacotherapeutics of the Integumentary System
  • Systemic Pharmacotherapeutics of the Muscular System
  • Systemic Pharmacotherapeutics of the Nervous System
  • Systemic Pharmacotherapeutics of the Reproductive System
  • Systemic Pharmacotherapeutics of the Respiratory System
  • Systemic Pharmacotherapeutics of the Urinary System
  • Chemotherapeutics Introduction
  • Anthelmintics
  • Antibacterial Agents
  • Antifungal Agents
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Antiseptics and Disinfectants
  • Antiviral Agents and Biologic Response Modifiers
  • Ectoparasiticides
  • Growth Promotants and Production Enhancers
  • Vaccines and Immunotherapy
Topics in Antineoplastic Agents
  • Overview of Antineoplastic Agents
  • Alkylating Agents
  • Antimetabolites
  • Mitotic Inhibitors
  • Antineoplastic Antibiotics
  • Hormonal Agents
  • Miscellaneous Antineoplastic Agents
  • Ancillary Antineoplastic Agents
  • Treatment of Canine Lymphoma
     
    • Merck Manual
    • >
    • Veterinary Professionals
    • >
    • Pharmacology
    • >
    • Antineoplastic Agents
    • 4
     
    Treatment of Canine Lymphoma

    Share This

    Lymphoma is the canine tumor most frequently treated with chemotherapy. It is the most common hematopoietic neoplasia of dogs (see Canine Lymphoma) and cats and is also among the most responsive to chemotherapy. Four antineoplastic agents, vincristine, cyclophosphamide, doxorubicin, and prednisone, form the basis for many lymphoma treatment protocols. Treatments based on these 4 drugs are often abbreviated as CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin® [a trade name of vincristine], and prednisone) protocols (see Antineoplastic Agents: Multidrug Chemotherapy for Treatment of Canine Lymphoma (sample induction protocol) aTables).

    Table 2

    PrintOpen table in new window Open table in new window
    Multidrug Chemotherapy for Treatment of Canine Lymphoma (sample induction protocol) a

    Drug

    Dosage

    Schedule

    l-Asparaginase

    10,000 IU/m2, SC

    Wk 1

    Vincristine

    0.5–0.7 mg/m2, IV

    Wk 1, 3, 6, 8, 11, 13. 16, and 18

    Cyclophosphamide

    250 mg/m2, IV or PO

    Wk 2, 7, 12, and 17

    Doxorubicin

    30 mg/m2, IV, for dogs >10 kg; 1 mg/kg for dogs <10 kg

    Wk 4, 9, 14, and 19

    Prednisone

    2 mg/kg, PO, sid

    For 1st week, then 1.5 mg/kg, PO, sid for 7 days, then 1 mg/kg, PO, sid for 7 days, then 0.5 mg/kg, PO, sid for 7 days, then discontinue

    a This table is intended to provide a typical treatment approach; however, there are nearly 40 published protocols for the management of lymphoma in dogs.

    A discontinuous chemotherapy protocol is used more commonly in veterinary oncology than maintenance or continuous chemotherapy. Discontinuous chemotherapy in dogs appears to lead to the same or similar remission and survival time as a traditional maintenance protocol. In this approach, all chemotherapy is discontinued for patients that are in complete remission at the end of the treatment protocol. At the first signs of recurrence of lymphoma, reinduction using the original chemotherapy protocol should be used. Studies have suggested that dogs receiving a discontinuous protocol were more likely to achieve a second remission when they relapsed than dogs that received longterm or maintenance chemotherapy. If reinduction fails, use of rescue protocols should be considered.

    Other lymphoma protocols include a non-doxorubicin based combination protocol (COP) or a protocol consisting solely of doxorubicin administered every 3 wk. These protocols are generally well tolerated, less expensive, and easy to administer but are considered to be less effective than a CHOP protocol.

    CHOP protocols also are the most common lymphoma chemotherapy protocols in cats, although there is no consensus treatment protocol recommended for this species. In general, fewer studies document the clinical effectiveness of various CHOP combinations in cats than in dogs.

    Last full review/revision March 2012 by Deborah T. Kochevar, DVM, PhD, DACVCP; Lisa G. Barber, DVM, DACVIM (Oncology); Kristine E. Burgess, MS, DVM, DACVIM (Oncology)

    Buy the Book

    Back to Top

    Previous: Ancillary Antineoplastic Agents

    Next: Overview of Antiseptics and Disinfectants

    Audio
    Figures
    Photographs
    Sidebars
    Tables
    Videos

    Copyright     © 2010-2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use